Genetic Testing Transactions and Valuations

Between Q1 2020 and Q3 2024, over $94 billion was invested across 1,798 M&A transactions within the genetic testing industry. This activity highlights the rising value of platforms focused on health DNA tests, ancestry analysis, and personalized trait reports. Investors are increasingly drawn to genetic testing companies that provide accessible, science-backed health and ancestry insights through scalable, consumer-friendly platforms with applications beyond traditional healthcare. 

The genetic testing sector is evolving to meet the needs of a health-conscious population seeking personalized insights and preventative healthcare solutions. Platforms in this space collect, analyze, and interpret genetic data, delivering information that helps individuals understand hereditary health risks, lifestyle implications, and ancestry connections. Companies that enhance user engagement through intuitive, easy-to-navigate trait reports and health DNA insights are particularly attractive to investors. Multi-platform data integration and customized wellness recommendations make companies valuable in the M&A landscape. 

Increasingly, genetic testing companies are leveraging machine learning and AI technologies to improve their offerings. These innovations can refine ancestry tracking, personalize health reports, and predict user-specific genetic traits, adding further value to the customer experience. With the continued rise of consumer interest in genetic health and ancestry data, the sector’s importance in the broader health and wellness market is only expected to grow.

• This analysis is based on a set of public and private M&A transactions in the genetic testing sector, focusing on enterprise value (EV) multiples relative to revenue (EV/revenue) and EBITDA (EV/EBITDA). The valuation data reflects current market behavior and investor sentiment toward growth and profitability within genetic testing services.
• The EV/revenue multiples range from 1x to 23x, with a mean of 5x and a median of 3x. Companies commanding higher revenue multiples often have a well-established user base, advanced genetic testing capabilities, and use cutting-edge technologies such as AI and machine learning. These technologies enhance the accuracy and personalization of genetic insights, driving consistent revenue growth and making these companies more attractive to investors.
• The EV/EBITDA multiples show a broader range, from 5x to 51x, with a mean of 19x and a median of 17x. This variation indicates differing profitability levels within the genetic testing industry. Companies with scalable models through advanced technology generally achieve higher EBITDA multiples. High-growth platforms focusing on expanding their testing services and customer base can attract premium valuations, emphasizing profitability and growth potential.

• Between Q1 2020 and Q3 2024, approximately $94 billion was invested across 1,798 M&A transactions in the genetic testing industry. This period reflects a dynamic investment environment, with funding levels heavily influenced by macroeconomic conditions such as public healthcare spending and interest rate fluctuations, which drive volatility in capital markets. These factors have led to notable fluctuations in both capital invested and deal count, indicating varying levels of investor interest and market consolidation.
• Q4 2021 marked the highest capital investment, reaching $22 billion across 142 deals. This spike suggests a significant increase in high-value transactions, likely driven by heightened demand for personalized health applications, consumer diagnostics, and increased healthcare spending during COVID-19.
• Q2 2021 recorded the most transactions, with 126 deals and a capital investment of $17 billion. This peak in deal count reflects strong interest in smaller and mid-sized acquisitions, likely from companies seeking to expand their offerings in consumer health insights and wellness. The surge in deal activity highlights a period of consolidation and strategic acquisitions within the industry.
• After several quarters of declining investment, Q3 2024 saw a modest rebound, with $1.26 billion invested across 66 deals. This uptick reflects an abundance of smaller transactions, driven by a growing interest in acquiring early stage technologies. Investors are increasingly targeting emerging innovations within the genetic testing sector, focusing on strategic acquisitions that promise future growth potential rather than immediate large-scale expansion.

• The genetic testing industry has experienced significant M&A activity, with the United States leading at 65% of capital invested and 42% of the total deal count. This high level of investment highlights the US market’s maturity and its capacity to attract substantial capital for advancements in personalized health services and consumer diagnostics.
• European acquirers contributed significantly, with France accounting for 9% of capital invested and 5% of deal count. German and British acquirers were also active in these sector, with Germany focusing on high-value deals that emphasize advancements in digital health, while the UK’s 8% of deal count reflects a vibrant market for smaller, innovation-driven transactions.
• Secondary markets, including Spain and Italy, show steady activity, each holding around 3 to 4% of the deal count. Acquirers in these countries have invested in genetic testing through targeted acquisitions that support regional healthcare innovations and personalized medicine initiatives. Emerging regions, such as Brazil, represent 3% of the deal count, indicating growing interest in Latin America as healthcare markets expand.

• Mergers and acquisitions account for the highest deal count, with 961 transactions totaling $60 billion. This high activity reflects ongoing consolidation in the industry as companies seek to expand their service offerings and integrate complementary technologies.
• Leveraged buyouts (LBOs) represent a significant portion of capital invested, with approximately $32 billion across 795 deals. This high investment level shows a strong focus on buyouts within the genetic testing sector, where private equity firms often leverage debt to acquire and scale companies, streamlining operations and enhancing profitability. These transactions typically target companies with established consumer bases and marketable platforms.
• Corporate divestitures accounted for $14 billion across 245 deals. This type of transaction indicates a trend where companies spin off non-core assets, allowing them to focus more strategically on genetic testing and personalized healthcare advancements.
• Secondary buyouts represent a notable investment of $19 billion, though only across 48 deals. These transactions involve selling portfolio companies from one private equity firm to another, often aiming for a fresh perspective on scaling opportunities within the genetic testing market.

---

For acquirers, companies in the genetic testing industry present a strategic entry point into a consumer-driven market with growing relevance to personalized healthcare. US acquirers have significantly influenced the sector, leading with a high number of acquisitions that reflect strong interest in domestic expansion and technological integration. The period saw an abundance of smaller transactions, driven by the pursuit of early stage technologies with high growth potential. Additionally, the integration of AI has transformed the industry, increasing data accuracy and personalized insights, making genetic testing companies even more attractive assets as AI continues to refine health data applications and consumer engagement. The momentum and potential in the sector positions genetic testing as a key area for those looking to capitalize on advancements in health data and personalized consumer insights.

Source: KMPG, Imarc, Pitchbook Data.